Navigation Links
Vivakor Announces New Acquisition Strategy
Date:12/9/2009

CORALVILLE, Iowa, Dec. 9 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced its acquisition strategy for the next 12 months. Executive Chairman, Matt Nicosia detailed the key points of the strategy: "We are currently looking at specific transactions involving companies with technologies that fit neatly into our 'hub and spoke' model, as well as companies which have existing commercialization channels that serve our own commercialization strategies for products developed internally." When asked about the timing of any future acquisitions, Mr. Nicosia responded, "We are looking at opportunities all the time. When one appears which fits within our stated strategy, we'll move forward with all due course." Future announcements of any acquisitions will be made as material events occur.

About Vivakor, Inc.

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and markets and business strategies. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact:

Vivakor Investor Relations

c/o IME Advisors

(888) 648-8485

SOURCE Vivakor, Inc.


'/>"/>
SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Heska Announces Extension of Credit Agreement With Wells Fargo
2. NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock
3. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
4. Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
5. RecoverCare Announces the Relocation of Corporate Headquarters to Louisville
6. Global Announces Contract To Acquire New Business
7. BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in Chinas National Insurance Catalog
8. ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer
9. Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
10. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
11. CompuCyte Announces the Release of Four-Laser Imaging Cytometers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
(Date:1/19/2017)... BEACH, Florida , January 19, 2017 /PRNewswire/ ... incoming Trump administration appears serious about reducing the ... advancements and innovation in the medical drug industry, ... forge ahead with new clinical trials and development ... Pharma companies forging ahead with recent developments include:  ...
(Date:1/19/2017)... -- The Global Therapy Partnering Terms and Agreements since ... and agreements entered into by the world,s leading healthcare ... deals by value - Deals listed by company A-Z, ... report provides understanding and access to the partnering deals ... companies. The report provides an analysis of partnering ...
Breaking Medicine Technology:
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Source ... botanicals and 100 percent pure essential oils, announced the company had a successful visit ... , The annual ECRM event gives companies that work in the nutritional, sports and ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out of Australia ... attended the January ECRM trade show in Hilton Head, SC. , International Protein ... to create a line of products that would elevate her fitness regime. At this ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale ... published author, Kimberly Cordoves, a mother of three in Oklahoma City, and a devoted woman ... of writing a book has been in the back of my mind for years, but ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
Breaking Medicine News(10 mins):